Vagus Nerve Stimulation Shows Promise in Treating Drug-Resistant Epilepsy

Strategic Insights -

Researchers at Mugla Sitki Kocman University Faculty of Medicine have reported significant results in the use of vagus nerve stimulation (VNS) as a treatment for drug-resistant epilepsy (DRE). The study, which included 40 patients, found that VNS implantation led to a more than 50% reduction in epileptic seizures in 62.5% of patients. Furthermore, the study demonstrated that VNS is an effective treatment option for patients with DRE.

Key Takeaways:

  • The study included 40 patients diagnosed with DRE who underwent VNS implantation at least one year prior.
  • Of the 40 patients, 42.5% were female and 57.5% were male, with a mean age of 37.2±11.2 years and an average duration of epilepsy of 24.7±10.7 years.
  • The median seizure frequency prior to VNS implantation was 20 per month, with a median values for VNS output current and VNS magnet current of 1.50 and 1.75 milliamperes, respectively.
  • The study found that VNS led to a more than 50% reduction in epileptic seizures in 62.5% of patients, while less than 50% reduction was seen in 25% of patients.
  • The researchers concluded that VNS is an important treatment option for patients with DRE.

Statistics:

  • 62.5% of patients experienced a more than 50% reduction in epileptic seizures following VNS implantation.
  • 25% of patients experienced less than 50% reduction in epileptic seizures following VNS implantation.
  • The median seizure frequency prior to VNS implantation was 20 per month.
  • The mean age of the patients was 37.2±11.2 years.
  • The average duration of epilepsy in the patients was 24.7±10.7 years.

Sources:

  • Vagus Nerve Stimulation in Drug-resistant Epilepsy: A Single-center Experience. Archives of Epilepsy, 2025,31(3):115-120.
  • https://doi-org.sdpl.idm.oclc.org/10.4274/ArchEpilepsy.2025.25190 (free version of the journal article is available)